The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
In human anatomy, the inframammary fold (IMF), inframammary crease or inframammary line is the natural lower boundary of the breast; the place where the breast and the chest meet. The choice of the term depends on the prominence of the feature. It is also sometimes called the inframammary ligament. From the cosmetological point of view, it is an important aesthetic component of the breast which should be taken into consideration during various kinds of breast surgery. Histologically, the inframammary fold is an intrinsic dermal structure consisting of regular arrays of collagen held in place by a specialized superficial fascia system. The fold is formed by the fusion of the superficial and mammary fasciae.
Eli Lilly also markets fluoxetine in a fixed-dose combination with olanzapine as olanzapine/fluoxetine (Symbyax), which was approved by the US Food and Drug Administration (FDA) for the treatment of depressive episodes of bipolar I disorder in 2003 and for treatment-resistant depression in 2009.
Side effects from therapeutic use can be much more varied depending on the location of injection and the dose of toxin injected. In general, side effects from therapeutic use can be more serious than those that arise during cosmetic use. These can arise from paralysis of critical muscle groups and can include arrhythmia, heart attack, and in some cases, seizures, respiratory arrest, and death. Additionally, side effects common in cosmetic use are also common in therapeutic use, including trouble swallowing, muscle weakness, allergic reactions, and flu-like syndromes. In response to the occurrence of these side effects, in 2008, the US Food and Drug Administration (FDA) notified the public of the potential dangers of the botulinum toxin as a therapeutic. Namely, the toxin can spread to areas distant from the site of injection and paralyze unintended muscle groups, especially when used for treating muscle spasticity in children treated for cerebral palsy. In 2009, the FDA announced that boxed warnings would be added to available botulinum toxin products, warning of their ability to spread from the injection site. However, the clinical use of botulinum toxin A in children with cerebral palsy has been proven to be safe with minimal side effects. Additionally, the FDA announced name changes to several botulinum toxin products, to emphasize that the products are not interchangeable and require different doses for proper use.
In October 2023, former Mongolian president Elbegdorj Tsakhia wrote to CNN, expressing his opposition to the death penalty and he cited Singapore as an example. Stating that Mongolia had abolished capital punishment and the crime rate in Mongolia never increased in the aftermath, Elbegdorj stated that he was concerned with the past 16 executions of low to mid-level drug traffickers in Singapore since March 2022, especially the July 2023 hanging of Saridewi Djamani (Singapore's first female to be put to death since 2004), and while he avers his respect for Singapore in terms of its prosperity and stability, Elbegdorj hoped that Singapore could re-evaluate the effectiveness of using the death penalty to curb drug crimes in favour of eventual abolition, due to the death penalty not able to fully uproot the cause of drug trafficking. He also stated that with the newly elected president Tharman Shanmugaratnam taking office, he hoped that the president could affirm the presidential powers of granting clemency to those on death row to soften the government's retentionist stance on capital punishment. In 2024, anti-death penalty activist Kokila Annamalai was the first activist within Singapore to publicly refuse to comply with the Protection from Online Falsehoods and Manipulation Act (POFMA) after the Singaporean government accused her of posting false information about its actions on social media concerning its use of the death penalty.
==== Cancer ==== According to the American Cancer Society, there is some evidence that ultraviolet light therapy may be effective in helping treat certain kinds of skin cancer, and ultraviolet blood irradiation therapy is established for this application. However, alternative uses of light for cancer treatment – light box therapy and colored light therapy – are not supported by evidence. Photodynamic therapy (often with red light) is used to treat certain superficial non-melanoma skin cancers.
Sources: en.wikipedia.org
Tim Hortons had a presence on a number of military bases, including Kandahar in Afghanistan, although this latter outlet was principally intended for Canadian Armed Forces and allied military personnel. Three more outlets were in military bases at Aberdeen Proving Ground, Maryland, Fort Knox, Kentucky, and Naval Station Norfolk, Virginia. The latest location is at Camp Adazi in Latvia.
No doubt the preoccupation with widely extended geographical ornithology, was fostered by the immensity of the areas over which British rule or influence stretched during the 19th century and for some time afterwards. The bird collectors of the Victorian era observed the variations in bird forms and habits across geographic regions, noting local specialization and variation in widespread species. The collections of museums and private collectors grew with contributions from various parts of the world. The naming of species with binomials and the organization of birds into groups based on their similarities became the main work of museum specialists. The variations in widespread birds across geographical regions caused the introduction of trinomial names.
=== In children === While type 1 diabetes is more prevalent in pediatric diabetes, type 2 diabetes has increasing prevalence, accounting for some 33% of new diagnoses. Risk factors for type 2 diabetes include ethnicity, family history, sedentary lifestyle, unhealthy diet, a mother with gestational diabetes, female gender, and obesity. Children with type 2 diabetes have increased risk of developing complications, which include insulin resistance, hyperglycemia, polyuria, ketosis, and dehydration. Early recognition, screening, treatment, and education of diabetic children are needed to prevent long-term disease complications. Screening for type 2 diabetes typically starts at 10 years old for obese children and those who have at least two risk factors. Diagnostic criteria include plasma blood glucose of more than 200 mg per deciliter (dl) or a fasting blood glucose above 126 mg per dl in children with overt symptoms. Differentiating type 1 from type 2 diabetes may include assessment of fasting blood insulin or C-peptide, or determination of autoantibodies for type 1 diabetes.
=== Adelaide Crows–Kurt Tippett contract scandal === During the trade period leading up to the 2013 season, Adelaide Crows forward Kurt Tippett sought to be traded. During trade negotiations, information was uncovered which brought into question the legality under AFL rules of Tippett's 2009 contract extension with Adelaide. The AFL investigated Tippett's contract during October and November, and charged Tippett and Adelaide with a total of eleven charges relating to draft tampering and breaching the total player payments, including:
=== Episil - oral mucositis pain === Oral mucositis is a severe side-effect of chemotherapy or radiotherapy during cancer treatment, and is often a dose-limiting factor in treatment. episil is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal film that mechanically protects the sensitized and sore epithelium of the oral cavity. It has been demonstrated in several clinical trials that episil gives an immediate and significant reduction of pain. This analgesic effect was maintained over at least 8 hours following administration. The treatment was reported to be safe and well tolerated. The product is registered as a medical device in a wide range of countries, including the European Union and the United States.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.